Niagen Bioscience (NAGE) Stock Statistics & Valuation Metrics

Niagen Bioscience has a market cap or net worth of $291.50M. The enterprise value is $227.53M.

Niagen Bioscience has 79,644,325 shares outstanding. The number of shares has decreased by -2.65% in one year.

Niagen Bioscience’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is 15.61%.

The current PE Ratio of Niagen Bioscience is 13.9. Niagen Bioscience’s PEG ratio is 0.24.

In the last 12 months, Niagen Bioscience had revenue of 129.42M and earned 17.38M in profits. Earnings per share was 0.22.

In the last 12 months, operating cash flow was 4.37M and capital expenditures -321.00K, giving a free cash flow of 4.05M billion.

Niagen Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Niagen Bioscience upcoming earnings date is Aug 12, 2026, After Close (Confirmed).

Niagen Bioscience as a current ratio of 4.86, with Debt / Equity ratio of 3.13%

In the past 12 months, Niagen Bioscience has paid 810.00K in taxes.

Niagen Bioscience EV to EBITDA ratio is 28.05, with an EV/FCF ratio of 33.59.

Niagen Bioscience has $66.55M in cash and marketable securities with $2.58M in debt, giving a net cash position of $63.97M billion.

Gross margin is 64.28%, with operating margin of 11.05%, and net profit margin of 13.43%.

The average price target for Niagen Bioscience is $11.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy